• Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

    •
    Bulletin of problems biology and medicine / Issue 2 Part 1 (150), 2019 / MELATONIN AS POTENTIAL CARDIOPROTECTOR: EXPERIMENTAL – CLINICAL ANALISIS OF EFFECTITY

    Zaychenko A. V., Gorchakova N. A., Klymenko E. V., Yakovleva N. Yu., Sinitsina O. S

    MELATONIN AS POTENTIAL CARDIOPROTECTOR: EXPERIMENTAL – CLINICAL ANALISIS OF EFFECTITY

    About the author:

    Zaychenko A. V., Gorchakova N. A., Klymenko E. V., Yakovleva N. Yu., Sinitsina O. S

    Heading:

    LITERATURE REVIEWS

    Type of article:

    Scentific article

    Annotation:

    In review it was stated melatonin influence on the cardiovascular system. It was shown the cardioprotective and antihypertensive effects of melatonin. It is known that melatonin is synthesided by pineal gland though it is produced by numerous mammalian organs with the prominent maximum at night. Melatonin normalizes sleepwakefullness rhythm. Melatonin has protective effect on endothelial function, favourable profile on cardiovascular system and metabolic effects, shortens vascular aging. It hasn`t shown drug-related adverse effects. There are many reports about role of melatonin on carbohydrate metabolism, relationships between melatonin, insulin, glucagon and signaling processes, the blood glucose regulation in the islet. It has been shown age dynamics of the melatonin synthesis. Melatonin has influence on the all organs and systems, last years expecial interest is associated with cardio-vascular system. Investigations have been shown the beneficial effects of melatonin on the cardiovascular system in experiments and clinics. In the experiments on isolated rats hearts melatonin in ischemia/reperfusion significantly reduced the duration of ventricular tachycardia, fibrillation and restored ventricular function. It was also investigated melatonin’s scavengering activity and its ability to measure contractile function. Besides of influence on contractility, melatonin slows down cardiac contractions rates, oppresses apoptosis, diminishes zone of myocardial infarction. Melatonin’s antioxidant action is connected with its stimulatory effect on superoxiddismutase, glutathione peroxidase, glutathionereductase, glucose-6-phosphatase dehydrogenase activity and inhibitory effect on the inducible NO-synthase. Melatonin reduced the increased lipid peroxidation and transaminase activity in rats received fluoxetin. Rats received melatonin in combination with fluoxetine showed the reduction in the degree of degeneration and inflammatory changes in different tissues. In the patients with coronary disease it was discovered the lower content of melatonin. It was also investigated that the acute myocardial infarction is connected with a nocturnal serum melatonin stress. It was stated that melatonin introduction is associated with antianginal and antiіchemic effects, indicating the improvement of contractile function. It was shown that melatonin may reduce blood pressure. Melatonin’s excretion in enterocytes increased during gatric ulcer in oncology patients that’s why melatonin introduction to them is usefal. Melatonin is the molecular marker which is characterizided by integral processes in cardiac and neuro-immune-endocrine systems and its content can be verified by non-invasive methods in peripheral tissues and biological fluids of organism. It is known that arterial hypertension may be connected with the left ventricular hypertrophy. It is characterized by complex changes in the cardiac structure, including cardiomyocites growing and noncardiomyocites alteration that cause remodeling of myocardium. It was shown that in pathological cardiac processes there were changes of mechanical neurohormonal and cytokine routes influences connected with melatonin level decrease. It was found reduce level of melatonin in the nocturnal serum of the rats with spontaneous hypertension and the melatonin administration reduces blood pressure to normal range in these animals. There are data that in spontaneously hypertensive rats blood pressure decreased after 6 weeks of melatonin treatment in the dose 10 mg/kg. That was connected with a reduction in renal tissue inflammation, decrease oxidative stress and lowering the level of proinflammatory transcription factors in the kidney. It was foun reduced level of melatonin in subjects suffering from nondippered hypertension. Although melatonin did not prevent the development of left ventricular hypertrophy it reduced hydroxyproline content and its concentration in the left ventricular cells. This effect of melatonin was associated with reduction of the oxidative stress. The antioxidative influence was proved by fact that of melatonin is able to attenuate fibrosis in the hypertensive ventricle that may functionally desirable. Melatonin treatment of older rats had worse restoration of acetylcholine synthesis compared with the rats of control group. Melatonin decreased not only arterial pressure, but also level of serotonin and norepinephrine. Melatonin improves parasympathetic stimulation in the pathologic processes. The obtained data showed that melatonin have therapeutic ability in the treatment of several cardiovascular diseases.

    Tags:

    melatonin, ischemia/reperfusion, cardioprotection, antihypertensive influence

    Bibliography:

    1. Arushanyan EB. Antistressornyie vozmozhnosti epifizarnogo melatonina. Melatonin v norme i patologii. 2004; 198-222. [in Russian].
    2. Srinivasan V, Gobbi G, Shillcutt SD, Suzen S. Melatonin: Therapeutic Value and Neuroprotection: CRC Press; 2015. 573 p.
    3. Kaladze NN, Sobolev EM, Skoromnaya NN. Itogi i perspektivyi izucheniya fiziologicheskih, patogeneticheskih i farmakologicheskih effektov melatonina. Zdorove rebenka. 2010;2:18-35. [in Russian].
    4. Favero G, Franceschetti L, Buffoli B, Moghadasian MH, Reiter RJ, Rodella LF, et al. Melatonin: protection against age-related cardiac pathology. Ageing Research Reviews. 2017;35:336-49.
    5. Aylamazyan EK, Evsyukova II, Yarmolinskaya MI. Rol melatonina v razvitii gestatsionnogo saharnogo diabeta. Zhurnal akusherstva i zhenskih bolezney. 2018;67(1):85-91. [in Russian].
    6. Saper CB. The central circadian timing system. Current opinion in neurobiology. 2013;23(5):747-51.
    7. Smirnov AN. Yadernyie retseptoryi melatonina. Biohimiya. 2001;66(1):28-36. [in Russian].
    8. Tan DX, Manchester LC, Liu X, Rosales‐Corral SA, Acuna‐Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. Journal of pineal research. 2013;54(2): 127-38.
    9. Reiter R, Rosales-Corral S, Manchester L, Tan DX. Peripheral reproductive organ health and melatonin: ready for prime time. International journal of molecular sciences. 2013;14(4):7231-72.
    10. Venegas C, García JA, Escames G, Ortiz F, López A, Doerrier C, et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52:217‐27.
    11. Ren W, Liu G, Chen S, Yin J, Wang J, Tan B, et al. Melatonin signaling in T cells: Functions and applications. Journal of pineal research. 2017;62(3):e12394.
    12. Söderquist F, Hellström PM, Cunningham JL. Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2. PloS one. 2015;10(3):e0120195.
    13. Peschke E, Bähr I, Mühlbauer E. Experimental and clinical aspects of melatonin and clock genes in diabetes. Journal of pineal research. 2015;59(1):1-2.
    14. Bähr I, Mühlbauer E, Schucht, H, Peschke E. Melatonin stimulates glucagon secretion in vitro and in vivo. Journal of pineal research. 2011;50(3):336-44.
    15. Zuev VA, Trifonov, NI, Linkova NS, Kvetnaya TV. Melatonin kak molekulyarnyiy marker vozrastnoy patologii. Uspehi gerontol. 2017;30(1):62. [in Russian].
    16. Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: pharmacology, functions and therapeutic benefits. Current neuropharmacology. 2017;15(3):434-43.
    17. Acuña-Castroviejo D, Escames G, Venegas C, Diaz-Casado ME, Lima-Cabello E, López LC, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cellular and molecular life sciences. 2014;71(16):2997-3025.
    18. Akinci A, Esrefoglu M, Cetin A, Ates B. Melatonin is more effective than ascorbic acid and β-carotene in improvement of gastric mucosal damage induced by intensive stress. Archives of medical science: AMS. 2015;11(5):1129-36.
    19. Khaksar M, Oryan A, Sayyari M, Rezabakhsh A, Rahbarghazi R. Protective effects of melatonin on long-term administration of fluoxetine in rats. Experimental and toxicologic pathology. 2017;69(8):564-74.
    20. Gubin GD, Weinert D, Bolotnova VT. Age-dependent changes of the temporal order-causes and treatment. Current aging science. 2016;9(1): 14-25.
    21. Gursoy AY, Kiseli M, Caglar GS. Melatonin in aging women. Climacteric. 2015;18(6):790-6.
    22. Arushanian EB. Pineal hormone melatonin in complex pharmacotherapy of brain and somatic disorders. Eksperimental’naia i klinicheskaia farmakologiia. 2011;74(9):39-45.
    23. Bespyatyih AYu, Brodskiy VYa, Burlakova OV, Golichenkov LA, Voznesenskaya DB, Kolesnikov AYu, i dr. Melatonin: teoriya i praktika. M.: Medpraktika; 2009. 100 s. [in Russian].
    24. Cardinali DP, Hardeland R. Inflammaging, metabolic syndrome and melatonin: a call for treatment studies. Neuroendocrinology. 2017;104(4):382-97.
    25. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Current topics in medicinal chemistry. 2002;2(2):181-97.
    26. Gulcin I, Buyukokuroglu ME, Oktay M, Kufrevioglu OI. On the in vitro antioxidative properties of melatonin. Journal of Pineal Research. 2002;33(3):167-71.
    27. Wagner G, Brandstätter R, Hermann A. Adrenergic and cholinergic regulation of in vitro melatonin release during ontogeny in the pineal gland of Long Evans rats. Neuroendocrinology. 2000;72(3):154-61.
    28. Khara MR, Shkumbatiuk OV, Kuchyrka LI, Holovetska ZS. Rol melatoninu v avtonomnii rehuliatsii sertsia shchuriv pry rozvytku adrenalinovoho poshkodzhennia zalezhno vid stati. Zdobutky klinichnoi i eksperymentalnoi medytsyny. 2012;(2):222. [in Ukrainian].
    29. Khara MR, Hevyk ZS. Statevi osoblyvosti reaktsii vehetatyvnoi nervovoi systemy starykh shchuriv na rozvytok nekrotychnoho protsesu v sertsi na tli melatoninu. Patolohiia. 2016;(1):15-8. [in Ukrainian].
    30. Khara MR, Kuchyrka LI. Rol melatoninu u kholiroreaktyvnosti miokarda honadektomovanykh shchuriv pry poshkodzhenni adrenalinom. Aktualni problemy transportnoi medytsyny: navkolyshnie seredovyshche; profesiine zdorovia; patolohiia. 2014;2(2):21-6. [in Ukrainian].
    31. Reiter RJ, Manchester LC, Fuentes-Broto L, Tan DX. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. Journal of Hypertension. 2010;28:7-12.
    32. Tsubanova NA, Berezniakova AI. Stan kardiohemodynamiky miokarda v umovakh ishemii ta reperfuzii na foni vvedennia strukturnoho analoha melatoninu. Zaporozhskyi medytsynskyi zhurnal. 2008;(6):129-31. [in Ukrainian].
    33. Fadieienko HD, Izmailova OV. Riven melatoninu u khvorykh na izolovanu HERKh ta khvorykh na HERKh u poiednanni z ishemichnoiu khvoroboiu sertsia ta yoho zviazok z klinikomorfolohichnymy osoblyvostiamy patolohii. Suchasna hastroenterolohiia. 2014;(6):25-31. [in Ukrainian].
    34. Roytberg GE. Vnutrennie bolezni. Serdechno-sosudistaya sistema. M.: Binom-press; 2007. 862 s. [in Russian].
    35. Rapoport SI, Golichenkova VA. Melatonin: teoriya i praktika. M.: Medpraktika-M; 2009. 99 s. [in Russian].
    36. Fabbian F, Bhatia S, De Giorgi A, Maietti E, Bhatia S, Shanbhag A, et al. Circadian periodicity of ischemic heart disease: a systematic review of the literature. Heart failure clinics. 2017;13(4):673-80.
    37. Ballyuzek MF, Mashkova MV, Arutyunyan AV, Dyuk VA. Melatonin kak marker tyazhesti kardiologicheskih narusheniy na etapah razvitiya sindroma kaheksii u onkologicheskih bolnyih raznogo vozrasta. Uspehi gerontologii. 2017;130(1):70-7. [in Russian].
    38. Lochner A, Marais E, Huisamen B. Melatonin and cardioprotection against ischaemia/reperfusion injury: What’s new? A review. Journal of pineal research. 2018;65(1):e12490.
    39. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. Journal of pineal research. 2008;44(1):16-25.
    40. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin for cardioprotection in ST elevation myocardial infarction: are we ready for the challenge? Heart. 2017;103:647-8.
    41. Burchakov DI, Uspenskaya YuB. Antioksidantnyiy, protivovospalitelnyiy i sedativnyiy effektyi melatonina: rezultatyi klinicheskih issledovaniy. Zhurnal nevrologii i psihiatrii im. CC Korsakova. 2017;117(4-2):67-73. [in Russian].
    42. Mihaylova ZD, Shalenkova MA. Rol melatonina u bolnyih s ostryim koronarnyim sindromom. Kardiologiya: Novosti. Mneniya. Obuchenie. 2017;2(13):39-44. [in Russian].
    43. Lochner A, Huisamen B, Nduhirabandi F. Cardioprotective effect of melatonin against ischaemia/reperfusion damage. Front Biosci (Elite Ed). 2013;5:305-15.
    44. Diez ER, Prados LV, Carrión A, Ponce ZAZ, Miatello RM. A novel electrophysiologic effect of melatonin on ischemia/reperfusion‐induced arrhythmias in isolated rat hearts. Journal of pineal research. 2009;46(2):155-60.
    45. Petrosillo G, Moro N, Ruggiero FM, Paradies G. Melatonin inhibits cardiolipin peroxidation in mitochondria and prevents the mitochondrial permeability transition and cytochrome c release. Free Radical Biology and Medicine. 2009;47(7):969-74.
    46. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Critical reviews in biochemistry and molecular biology. 2009;44(4):175-200.
    47. Yeung HM, Hung MW, Lau CF, Fung ML. Cardioprotective effects of melatonin against myocardial injuries induced by chronic intermittent hypoxia in rats. Journal of pineal research. 2015;58(1):12-25.
    48. Su H, Li J, Chen T, Li N, Xiao J, Wang S, et al. Melatonin attenuates angiotensin II-induced cardiomyocyte hypertrophy through the CyPA/CD147 signaling pathway. Molecular and cellular biochemistry. 2016;422(1-2):85-95.
    49. Patel V, Upaganlawar A, Zalawadia R, Balaraman R. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: a biochemical, electrocardiographic and histoarchitectural evaluation. European journal of pharmacology. 2010;644(1-3):160-8.
    50. Vazan R, Ravingerova T. Protective effect of melatonin against myocardial injury induced by epinephrine. Journal of physiology and biochemistry. 2015;71(1):43-9.
    51. Govender J, Loos B, Marais E, Engelbrecht AM. Mitochondrial catastrophe during doxorubicin‐induced cardiotoxicity: a review of the protective role of melatonin. Journal of pineal research. 2014;57(4):367-80.
    52. An R, Zhao L, Xi C, Li H, Shen G, Liu H, et al. Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. Basic research in cardiology. 2016;111(1):8.
    53. Lu Q, Yi X, Cheng X, Sun X, Yang X. Melatonin protects against myocardial hypertrophy induced by lipopolysaccharide. In Vitro Cellular & Developmental Biology-Animal. 2015;51(4):353-60.
    54. Zhai M, Liu Z, Zhang B, Jing L, Li B, Li K, et al. Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC‐1β: In vivo and in vitro studies. Journal of pineal research. 2017;63(3):e12433.
    55. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never‐ending interaction of melatonin with reactive oxygen and nitrogen species? Journal of pineal research. 2007;42(1):28-42.
    56. Reiter JR, Tan DX, Rosales-Corral S, Manchester CL. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini reviews in medicinal chemistry. 2013;13(3):373-84.
    57. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre‐Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. Journal of pineal research. 2016;61(3):253-78.
    58. Galano A, Medina ME, Tan DX, Reiter RJ. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. Journal of pineal research. 2015;58(1):107-16.
    59. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annual review of pharmacology and toxicology. 2016;56:361-83.
    60. Lochner A, Genade S, Davids A, Ytrehus K, Moolman JA. Short‐and long‐term effects of melatonin on myocardial post‐ischemic recovery. Journal of pineal research. 2006;40(1):56-63.
    61. Lamont K, Nduhirabandi F, Adam T, Thomas DP, Opie LH, Lecour S. Role of melatonin, melatonin receptors and STAT3 in the cardioprotective effect of chronic and moderate consumption of red wine. Biochemical and biophysical research communications. 2015;465(4):719-24.
    62. Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H, Reiter RJ. Melatonin as a naturally occurring co‐substrate of quinone reductase‐2, the putative MT3 melatonin membrane receptor: hypothesis and significance. Journal of pineal research. 2007;43(4):317-20.
    63. He B, Zhao Y, Xu L, Gao L, Su Y, Lin N, et al. The nuclear melatonin receptor ROR α is a novel endogenous defender against myocardial ischemia/ reperfusion injury. Journal of pineal research. 2016;60(3):313-26.
    64. Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol‐ and melatonin‐induced cardioprotection. Journal of pineal research. 2011;50(4):374-80.
    65. Nduhirabandi F, Lamont K, Albertyn Z, Opie LH, Lecour S. Role of toll‐like receptor 4 in melatonin‐induced cardioprotection. Journal of pineal research. 2016;60(1):39-47.
    66. Lau WW, Ng JK, Lee MM, Chan AS, Wong YH. Interleukin‐6 autocrine signaling mediates melatonin MT1/2 receptor‐induced STAT3 Tyr705 phosphorylation. Journal of pineal research. 2012;52(4):477-89.
    67. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003;8(10):1093-108.
    68. Chan AS, Lai FP, Lo RK, Voyno-Yasenetskaya TA, Stanbridge EJ, Wong YH. Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and-insensitive G proteins. Cellular signalling. 2002;14(3):249-57.
    69. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Progress in neurobiology. 2008;85(3):335-53.
    70. Genade S, Genis A, Ytrehus K, Huisamen B, Lochner A. Melatonin receptor‐mediated protection against myocardial ischaemia/reperfusion injury: role of its anti‐adrenergic actions. Journal of pineal research. 2008;45(4):449-58.
    71. Nduhirabandi F, Huisamen B, Strijdom H, Blackhurst D, Lochner A. Short‐term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity. Journal of pineal research. 2014;57(3):317-32.
    72. Yang Y, Duan W, Jin Z, Yi W, Yan J, Zhang S, et al. JAK 2/STAT 3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. Journal of pineal research. 2013;55(3):275-86.
    73. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. The FASEB journal. 2004;18(7):869-71.
    74.  Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation. 2005 Dec 20;112(25):3911-8.
    75. Wang Z, Liu D, Wang J, Liu S, Gao M, Ling EA, et al. Cytoprotective effects of melatonin on astroglial cells subjected to palmitic acid treatment in vitro. Journal of pineal research. 2012;52(2):253-64.
    76. Yu L, Sun Y, Cheng L, Jin Z, Yang Y, Zhai M, et al. Melatonin receptor‐mediated protection against myocardial ischemia/reperfusion injury: role of SIRT 1. Journal of pineal research. 2014;57(2):228-38.
    77. Zhai M, Li B, Duan W, Jing L, Zhan B, Zhang M, et al. Melatonin ameliorates myocardial ischemia reperfusion injury through SIRT 3‐dependent regulation of oxidative stress and apoptosis. Journal of Pineal Research. 2017;63(2):e12419.
    78. Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: An adjunct anti‐hypertensive agent. Clinical and Experimental Pharmacology and Physiology. 2018;45(8):755-66.
    79. Paulis L, Šimko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiological research. 2007;56(6):671-84.
    80. Simko F, Pechanova O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. Journal of pineal research. 2009;47(2):127-33.
    81. Simko F, Pechanova O. Recent trends in hypertension treatment: perspectives from animal studies. J. Hypertens. Suppl. 2009;27:1-4.
    82.  Enjuanes-Grau C, Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, Avanzas P. Blood pressure levels and pattern of melatonin secretion in a population of resident physicians on duty. Revista Española de Cardiología. 2012;65(06):576-7.
    83. Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004;43(2):192-7.
    84. Nava M, Quiroz Y, Vaziri ND, Rodríguez-Iturbe B. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2003 Mar;284(3):F447-54.
    85. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossma E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood pressure. 2003;12(1):19-24.
    86. Girouard H, Chulak C, Lejossec M, Lamontagne D, de Champlain J. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. Journal of hypertension. 2001;19(8):1369-77.
    87. Girouard H, Denault C, Chulak C, Champlain JD. Treatment by N-acetylcysteine and melatonin increases cardiac baroreflex and improves antioxidant reserve. American journal of hypertension. 2004;17(10):947-54.
    88.  Rahman MM, Kwon HS, Kim MJ, Go HK, Oak MH, Kim DH. Melatonin supplementation plus exercise behavior ameliorate insulin resistance, hypertension and fatigue in a rat model of type 2 diabetes mellitus. Biomedicine & pharmacotherapy. 2017;92:606-14.
    89.  Pechánová O, Zicha J, Paulis L, Zenebe W, Dobesová Z, Kojsová S, et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. European journal of pharmacology. 2007;561(1-3):129-36.
    90. Simko F, Pechanova O, Repova Bednarova K, Krajcirovicova K, Celec P, Kamodyova N, et al. Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin. Mediators of inflammation. 2014;204:e703175.
    91. Simko F, Pechanova O, Pelouch V, Krajcirovicova K, Mullerova M, Bednarova K, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. Journal of Hypertension. 2009;27:5-10.
    92. Cagnacci A, Arangino S, Angiolucci M, Melis GB, Facchinetti F, Malmusi S, et al. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clinical endocrinology. 2001;54(2):261-6.
    93. Nishiyama K, Yasue H, Moriyama Y, Tsunoda R, Ogawa H, Yoshimura M, et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. American heart journal. 2001;141(5):13A-17A.
    94. Ray CA. Melatonin attenuates the sympathetic nerve responses to orthostatic stress in humans. The Journal of physiology. 2003;551(3): 1043-8.
    95. Altman NG, Izci-Balserak B, Schopfer E, Jackson N, Rattanaumpawan P, Gehrman PR, et al. Sleep duration versus sleep insufficiency as predictors of cardiometabolic health outcomes. Sleep medicine. 2012;13(10):1261-70.
    96. Buxton OM, Marcelli E. Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in the United States. Social science & medicine. 2010;71(5):1027-36.
    97. Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. The American journal of medicine. 2006;119(10):898-902.
    98. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular health and risk management. 2011;7:577.
    99.  Pogan L, Bissonnette P, Parent L, Sauvé R. The effects of melatonin on Ca2+ homeostasis in endothelial cells. Journal of pineal research. 2002;33(1):37-47.
    100. Yildiz M, Sahin B, Sahin A. Acute effects of oral melatonin administration on arterial distensibility, as determined by carotid-femoral pulse wave velocity, in healthy young men. Experimental & Clinical Cardiology. 2006;11(4):311-3.
    101. van der Helm-van Mil AH, van Someren EJ, van den Boom R, van Buchem MA, de Craen AJ, Blauw GJ. No influence of melatonin on cerebral blood flow in humans. The Journal of Clinical Endocrinology & Metabolism. 2003;88(12):5989-94.
    102. Reiter RJ, Tan DX, Manchester C, Burillo SL, Juan MS, Mayo C. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. In Developments in Tryptophan and Serotonin Metabolism. 2003;527:539-48.
    103. Kilic ÜK. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol. J. Pharmacol. 2004;56:159-70.
    104.  Anwar MM, Meki ARM, Rahma HHA. Inhibitory effects of melatonin on vascular reactivity: possible role of vasoactive mediators. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology. 2001;130(3):357-67.
    105. Xia CM, Shao CH, Xin L, Wang YR, Ding CN, Wang J, et al. Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clinical and Experimental Pharmacology and Physiology. 2008;35(10):1258-64.
    106. Girouard H, Chulak C, LeJossec M, Lamontagne D, de Champlain J. Chronic antioxidant treatment improves sympathetic functions and β-adrenergic pathway in the spontaneously hypertensive rats. Journal of hypertension. 2003;21(1):179-88.

    Publication of the article:

    «Bulletin of problems biology and medicine» Issue 2 Part 1 (150), 2019 year, 26-35 pages, index UDK 577:154.365+001.3+616.31

    DOI:

    10.29254/2077-4214-2019-2-1-150-26-35